MarginsXMarginsX
Home › Markets › Health Care › GKOS

Glaukos Corporation (GKOS)

GKOS trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$244.88
-0.34% on the day
Market cap
$14.5B
Large cap
Revenue · 2025
$507.4M
+32.3% on 2024
Net income · 2025
-$187.7M
-37.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/0001193125-26-061944-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGKOS on NYSE
SectorHealth Care
IndustryMedical/Dental Instruments
CountryUnited States
IPO year2015
SEC CIK0001192448
SEC industry codeSurgical & Medical Instruments & Apparatus
Incorporated inDE

Financials · 2025

LineValue
Revenue$507.4M
Net income-$187.7M
Operating income-$199.6M
Net margin-37.0%
Operating margin-39.3%
Revenue growth+32.3%
Cash$90.8M
Total assets$893.5M
P/E (computed)Net income was not positive
P/S (computed)28.6×

Warning signs

Cash runway
Cash-flow positive
$162.3M cash at September 30, 2026
Share count, 1 year
+3.1%
2025-10-29 to 2026-10-26 · +21.3% over 3 years
Going-concern doubt
No
10-Q filed October 28, 2026
Insider net buying, 12 months
-$69.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-28
Cash and burn$162.3M cash; operating cash flow $11.9M a quarter.Report 2026-09-30
Shares outstanding59,196,870 (2026-10-26); 57,434,740 a year earlier; 48,799,581 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $69.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$211.0M$2.0M$38.6M$162.3MNo debt tags$690.3M10-Q 2026-10-28
Q2 2026
2026-06-30
$185.6M-$18.4M$14.8M$114.5MNo debt tags$612.8M10-Q 2026-07-29
Q1 2026
2026-03-31
$150.6M-$19.8M-$12.5M$104.2MNo debt tags$551.3M10-Q 2026-04-30
Q4 2025
2025-12-31
$143.1M-$133.7M$6.8M$90.8MNo debt tags$507.4M10-K 2026-02-23
Q3 2025
2025-09-30
$133.5M-$16.2M-$10.1M$98.2MNo debt tags$469.8M10-Q 2026-10-28
Q2 2025
2025-06-30
$124.1M-$19.7M$7.0M$100.8MNo debt tags$433.0M10-Q 2026-07-29
Q1 2025
2025-03-31
$106.7M-$18.1M-$18.5M$114.3MNo debt tags$404.5M10-Q 2026-04-30
Q4 2024
2024-12-31
$105.5M-$33.6M$507K$169.6MNo debt tags$383.5M10-K 2026-02-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32019-10-17
Latest annual report10-K2026-02-23
Latest quarterly / interim10-Q2026-10-28
Latest current report8-K2026-11-06
Latest proxyDEFA14A2026-04-16

Source: SEC EDGAR submissions feed, 1,020 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.5%
1 month+48.5%
3 months+29.7%
Year to date+117.6%
1 year+167.6%
From 52-week high-0.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical/Dental Instruments

TickerCompanyPriceDayMarket cap
SOLVSolventum Corporation$88.65-0.48%$15.0B
BAXBaxter International Inc.$25.54-1.05%$13.2B
PENPenumbra Inc.$320.62-0.09%$12.6B
PODDInsulet Corporation$145.29-4.72%$10.1B
GMEDGlobus Medical Inc.$70.50-2.27%$9.3B
WSTWest Pharmaceutical Services Inc.$417.80+0.33%$29.1B
DXCMDexCom Inc.$81.61-2.06%$30.4B
RMDResMed Inc.$238.19-0.56%$33.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier